HER2-Positive Breast Cancer | Topics

 
Numerically Improved pCR Not Significant With SD-101 Plus Pembrolizumab in HER2– Breast Cancer
June 07, 2021

Some improvement in pathological complete response may be possible with SD-101 plus pembrolizumab and paclitaxel in certain patients with HER2-negative breast cancer, but results are still uncertain.

De-escalated Neoadjuvant Trastuzumab/Pertuzumab Induced Sufficient Responses in HER2+/HR– Breast Cancer
June 06, 2021

With a de-escalation strategy for administration of trastuzumab and pertuzumab in the neoadjuvant setting, patients with HER2-positive, hormone receptor–negative breast cancer experienced high rates of response and survival.

Follow-up Analysis Found Similar Survival Rates of Chemotherapy With or Without Anthracyclines for ERBB2-Positive Breast Cancer
June 01, 2021

A 3-year follow-up analysis of event-free and overall survival revealed similar results for patients with stage II or III ERBB2-positive breast cancer treated with either neoadjuvant anthracycline and nonanthracycline treatment regimens.